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To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplas-
mic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/
or CD4 lymphocyte counts of <200/AL were randomized to receive dapsone/pyrimethamine
(200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks). The median CD4
lymphocyte count was 110/AL; 47.5% were seropositive for toxoplasma antibodies. The median
duration of follow-up was 483 days. In the intent-to-treat analysis, 12 cases of PCP and 14 of
toxoplasmic encephalitis occurred in the dapsone/pyrimethamine group and 13 and 20 cases,
respectively, in the aerosolized pentamidine group (adjusted relative risk for toxoplasmosis,
0.56; P = .10). However, only two of the 14 cases of toxoplasmic encephalitis in the dapsone/
pyrimethamine group developed during actual treatment. The mortality among the two groups
was similar. Dapsone/pyrimethamine was not tolerated by 30% of participants. A subanalysis of
240 matched, tolerant patients yielded a relative risk for toxoplasmosis of 0.21 (P = .014), a
result favoring the use of dapsone/pyrimethamine. Dapsone/pyrimethamine was as effective as
aerosolized pentamidine as prophylaxis for PCP and significantly reduced the incidence of toxo-
plasmic encephalitis among those participants who tolerated it.
Prophylaxis for opportunistic infections has had a strong
impact on the management of immunosuppressed human
immunodeficiency virus (HIV)—infected patients in recent
years, and epidemiological data indicate that Pneumocystis
carinii pneumonia (PCP) has become less frequent as a con-
sequence of prevention [1]. Aerosolized pentamidine be-
came available in Switzerland in 1987 and was subsequently
proven effective for both primary and secondary prophylaxis
for PCP in controlled trials [2, 3]. Among systemic prophy-
lactic agents, trimethoprim-sulfamethoxazole became widely
used [4] and was later shown to be more effective but also
more toxic than aerosolized pentamidine [5, 6]. Other combi-
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nations, such as dapsone and trimethoprim [7] or pyrimetha-
mine and sulfadiazine [8], have been used for treatment of
PCP before, but sparse data exist concerning their prophylac-
tic efficacy [9]. Only recently, the prophylactic efficacy of the
combination of dapsone and pyrimethamine against PCP
and toxoplasmosis was demonstrated [ 10].
Since in >95% of all AIDS patients with toxoplasmic en-
cephalitis there is serological evidence of previous infection
with Toxoplasma gondii [10-13], reactivation of a latent in-
fection is the principal pathogenetic step in the development
of toxoplasmic encephalitis during immunodeficiency. Con-
sidering the increasing frequency of toxoplasmic encephalitis
among AIDS-defining opportunistic infections [ 1] and the
50% seroprevalence of toxoplasma antibodies in Switzerland
[14], primary prophylaxis for toxoplasmic encephalitis seems
desirable and clinically important, at least for seropositive
patients.
The sequential inhibition of dihydrofolate reductase by
pyrimethamine and of dihydropteroate synthetase by sulfon-
amides and dapsone is the rationale for a combination regi-
men that blocks the folate metabolism in P. carinii and T.
gondii. Dapsone and pyrimethamine have been active
against both organisms in vitro and in murine models [ 15-
17]; therefore, this combination was chosen for evaluation as
combined prophylaxis for PCP and toxoplasmic encephali-
tis. Low cost and the potential for once-weekly administra-
tion [18] are additional attractive features of the dapsone/
pyrimethamine combination. As aerosolized pentamidine
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was the standard prophylaCtic agent against PCP at the time
the trial was designed, we planned a prospective, random-
ized comparison of dapsone/pyrimethamine and aerosolized
pentamidine administered as primary and secondary prophy-
laxis for PCP and as primary prophylaxis for toxoplasmic
encephalitis.
Methods
Study Population
The participants were adults with HIV infection and an
immunodeficiency score of at least 5. This score, for select-
ing patients with a high risk for PCP [2, 19], was determined
according to the following clinical and laboratory criteria: 5
points were assigned for a peripheral blood CD4 lymphocyte
count of <200/AL or AIDS (except Kaposi's sarcoma); 3
points for symptomatic HIV infection without AIDS; and 2
points for Kaposi's sarcoma, a CD4 lymphocyte count of
200-500/AL, or positivity for HIV p24 antigen in serum.
Previous PCP, previous prophylaxis with aerosolized penta-
midine, and simultaneous antiretroviral treatment were al-
lowed in the study protocol. Exclusion criteria were prior
toxoplasmic encephalitis, concurrent treatment with drugs
active against P. carinii or T. gondii, pregnancy, injection
drug use, and a serum creatinine level of >120 Amon. The
study design was approved by the ethical committees of the
participating hospitals, and all participants gave informed
consent.
Study Design
This controlled, open-label trial was conducted in 7
centers in Switzerland, 4 centers in Milan, Italy, and 1 center
in Besancon, France. Enrollment began in February 1991.
Participants were randomized to receive either 200 mg of
dapsone and 75 mg of pyrimethamine once weekly or 300
mg of aerosolized pentamidine every 4 weeks, by means of a
Respirgard II jet nebulizer (Marquest, Englewood, CO) and
under the supervision of a nurse. Block randomization was
used, with additional stratification by center, previous PCP,
and positivity or negativity for toxoplasma IgG, as deter-
mined by ELISA. Folinic acid was not routinely adminis-
tered. On the basis of the observation that failures of penta-
midine prophylaxis tend to occur early [2], participants who
had not previously received aerosolized pentamidine were
given a loading dose of three inhalations of 300 mg each
within 10-14 days; monthly inhalations took place there-
after.
The protocol allowed a change of treatment in case of
intolerance or the occurrence of breakthrough PCP. As of
October 1991, a high rate of treatment switches from dap-
sone/pyrimethamine to aerosolized pentamidine necessi-
tated a change of protocol: each study candidate first re-
ceived three trial doses of dapsone/pyrimethamine (200/75
mg once a week), and only those patients who tolerated these
doses were enrolled. A 2:1 randomization ratio in favor of
dapsone/pyrimethamine was additionally introduced to
compensate for the treatment switches.
Supply and Administration of Dapsone/Pyrimethamine
Because both dapsone and pyrimethamine were available
in Switzerland only as 25-mg tablets, the generic drugs were
assembled into one capsule containing 200 mg of dapsone
and 75 mg of pyrimethamine (G. Streuli and Co., Uznach,
Switzerland), thus enabling the participants to take only one
capsule once weekly. The capsules were analyzed and found
to contain, on average, 196 mg of dapsone and 75.5 mg of
pyrimethamine; the weight uniformity was within 10% for all
capsules examined. A pharmacokinetic evaluation of the
combination capsule involving three volunteers demon-
strated normal bioavailability in comparison to that of com-
mercially available tablets [20]. The combination capsules
were purchased for an average price of $0.15 each. The pa-
tients were instructed to take dapsone/pyrimethamine sepa-
rate from didanosine to avoid any possible interaction be-
tween the two treatments that might decrease dapsone
efficacy [21].
Follow-up of Patients and Clinical End Points
The participants were observed every 4 weeks and evalu-
ated for symptoms and adverse events as well as tested for
hematologic, renal, and hepatic function. During every visit,
patients were asked about their compliance and the number
of missed capsules was noted. An algorithm concerning the
management of adverse events was provided, allowing for
treatment switches (crossovers) in cases of moderate to se-
vere clinical symptoms clearly attributable to the study medi-
cation or in cases of persisting, severe hematologic toxicity.
Diagnoses of PCP or toxoplasmic encephalitis were consid-
ered as definite if the presence of P. carinii or T. gondii was
microscopically confirmed. A diagnosis of presumed PCP
was made according to World Health Organization criteria
[22] and required all of the following: dyspnea on exertion or
nonproductive cough of recent onset; diffuse interstitial infil-
trates evident on a chest roentgenogram; hypoxemia, with
arterial partial pressure of oxygen (p0 2) of <70 mmHg or an
increased arterial-alveolar oxygen difference; and no evi-
dence of bacterial pneumonia or of another condition that
would account for the symptoms. Because a brain biopsy is
not a routine diagnostic approach [11], most of the diagnoses
of toxoplasmic encephalitis were presumed on the basis of all
of the following: recent onset of a focal neurological abnor-
mality consistent with intracranial disease or a reduced level
of consciousness, evidence of intracranial lesion(s) on com-
puted tomography or magnetic resonance imaging, and posi-
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tivity for serum antibodies to toxoplasmosis or successful re-
sponse to antitoxoplasmic therapy [22].
Statistical Analysis
Primary end points were the occurrences of definite or pre-
sumed PCP or toxoplasmic encephalitis. The statistical analy-
ses were based on the intent-to-treat principle and included
events occurring until 31 December 1992. Where specified,
occurrence of PCP or toxoplasmic encephalitis during the
originally assigned treatment was also analyzed. For this pur-
pose, the duration was equal to the time of initial treatment,
and only those events that occurred during the treatment or
within 1 month of its discontinuation were considered. Two
patients who never started receiving the prophylaxis were
excluded from the analysis. Baseline characteristics were
compared with use of the X2
 test or Mann-Whitney test, as
appropriate. The probability of remaining free of disease was
calculated by means of Kaplan-Meier life-table analysis and
compared by log-rank test. Multivariate Cox proportional
hazards regression was used to estimate relative risks asso-
ciated with the regimens; the models were adjusted for CD4
lymphocyte counts at baseline and additionally for toxo-
plasma serology when the risk of toxoplasmic encephalitis
was evaluated.
Four interim analyses were planned, and rules for stop-
ping the trial were based on those of O'Brien and Fleming
[23]. The third interim analysis in December 1 992 revealed
no significant differences in the intent-to-treat analysis.
At this time, however, it became clear that the latter lost
power because of the frequent intolerance of dapsone/
pyrimethamine and subsequent switches to aerosolized
pentamidine. In addition, new data suggested that dapsone/
pyrimethamine [ 10] and possibly trimethoprim-sulfameth-
oxazole [24] prevent toxoplasmosis. Meanwhile, administra-
tion of trimethoprim-sulfamethoxazole became the standard
prophylaxis for PCP [5, 6, 25], and continuing the prophy-
lactic administration of aerosolized pentamidine to patients
who were seropositive for toxoplasmosis seemed unethical.
The trial was therefore stopped prematurely as of 31
December 1992.
Because the substantial number of switches from dapsone/
pyrimethamine to aerosolized pentamidine diminished the
power of the intent-to-treat analysis to detect a difference
between the effects of treatment [26], a subgroup analysis
was subsequently performed to evaluate the biological effect
ofdapsone/pyrimethamine. One group consisted ofall partic-
ipants randomized to receive dapsone/pyrimethamine who
did not need to withdraw from the treatment because ofintol-
erance and who had received no previous trial dose (n =
120). Of the 182 participants randomized to receive aeroso-
lized pentamidine and who fulfilled the same criteria, 120
were matched to the dapsone/pyrimethamine group
members according to their toxoplasma serology, their CD4
count (within 10 cells/AL in the < 200/AL range, within
±10% in the >200/AL range, and within ±20% in the >350/
AL range), and (when possible) their sex and date of random-
ization. The same end points were used as in the intent-to-
treat analysis. Both groups were then compared for
occurrence of PCP, toxoplasmic encephalitis, and death (log-
rank test and multivariate Cox regression analysis).
Results
Patients' Characteristics
A total of 533 patients started the treatment; 382 were
randomized before the institution of trial dosing on 1 Oc-
tober 1991, and 151 had tolerated the three (weekly) trial
doses of dapsone/pyrimethamine and were randomized
thereafter at a ratio of 2:1 favoring the dapsone/
pyrimethamine regimen. Overall, 291 participants were ran-
domized to receive dapsone/pyrimethamine and 242 to re-
ceive aerosolized pentamidine. Participants continued to be
monitored even if they prematurely discontinued taking the
study medication because of (1) opportunistic diseases or
treatment with drugs not permitted in the protocol (n = 56),
(2) patient-related reasons such as noncompliance or with-
drawal of consent (n = 97), (3) intolerance after switching to
the other treatment (n = 1), or (4) other reasons (n = 4). As
of 31 December 1992, 255 participants were still receiving
therapy (112, dapsone/pyrimethamine; 143, aerosolized
pentamidine), 150 had died, and 27 had been lost to follow-
up for >2 months. The median duration of follow-up was
483 days (449 days in the dapsone/pyrimethamine group
and 505 days in the aerosolized pentamidine group), and the
total observation times were 4, 113 patient-months (dap-
sone/pyrimethamine) and 3,659 patient-months (aeroso-
lized pentamidine), based on the original treatment assign-
ment.
The baseline characteristics of the two groups were well
balanced (table 1). The median age was 33.5 years, and 83%
of the patients were male. Only 19% had previously had PCP
and were thus receiving secondary PCP prophylaxis. The
seroprevalence of toxoplasma IgG was 47.5%. Significant dif-
ferences between the groups were observed only regarding
the risk for HIV infection and prior prophylaxis with aeroso-
lized pentamidine.
Occurrence of PCP
A total of 25 cases of PCP were observed, 19 in the 430
participants receiving primary prophylaxis and 6 in the 103
patients receiving secondary prophylaxis. The diagnosis of
PCP was confirmed microscopically in 24 cases and was pre-
sumptive in one case. PCP occurred in 12 participants
randomized to receive dapsone/pyrimethamine and in 13 al-
located to receive aerosolized pentamidine in the intent-to-
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Table 1. Baseline characteristics of HIV-infected patients who
received dapsone/pyrimethamine (DP) or aerosolized pentamidine
(AP) as prophylaxis for PCP and toxoplasmic encephalitis.
Prophylaxis group
DP AP
Characteristic (n = 291) (n = 242) P value
Median age (y) 34 33 .28
Male sex (%) 84 83 .63
Homosexual or bisexual (%) 43 34 .04
Injection drug use (%) 34 41 .11
Previous PCP (%) 18 21 .48
Previous use of AP (%) 26 42 <.001
Previous use of zidovudine or
didanosine (%) 90 91 .73
Median CD4 lymphocyte count
(per AL) 116 105 .30
Positivity for toxoplasma IgG (%) 46 49 .59
treat analysis (figure 1; P = .65, log-rank test). The adjusted
relative risk was 0.89 (95% confidence interval [CI], 0.39-
1.89; P = .71) for patients randomized to the dapsone/
pyrimethamine group in comparison with that for those ran-
domized to the aerosolized pentamidine group.
Three of 12 cases of PCP in the dapsone/pyrimethamine
group occurred between 184 and 414 days after a switch to
aerosolized pentamidine due to intolerance. An additional
two patients in each group developed PCP at least 1 month
after all treatment had been discontinued (table 2). The inci-
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Figure 1. Proportion of participants remaining free of PCP in an
intent-to-treat analysis. The adjusted relative risk of PCP was 0.87
(95% CI, 0.39-1.90) for those randomized to receive prophylaxis
with dapsone/pyrimethamine. Numbers of patients at risk are listed
above the time axis; DP = dapsoneipyrimethamine treatment
group (solid line), and AP = aerosolized pentamidine treatment
group (dashed line).
Table 2. Duration of follow-up and occurrence of clinical events
in primary and secondary analyses of participants in the dapsone/
pyrimethamine (DP) and aerosolized pentamidine (AP) prophy-
laxis groups.
Prophylaxis
group
Variable DP AP P value
Intent-to-treat analysis
Median follow-up (d) 449 505
Clinical event (no. of patients)
PCP 12 13 .65
Toxoplasmic encephalitis 14 20 .17
Death 77 73 .93
As-treated analysis*
Median follow-up (d) 226 379
Clinical event (no. of patients)
PCP 7 11 .63
Toxoplasmic encephalitis 2 17 <.005
Death 29 40 .84
Analysis of biological effectt
Median follow-up (d) 537 549
Clinical event (no. of patients)
PCP 7 5 .47
Toxoplasmic encephalitis 3 14 <.01
Death 40 41 .82
NOTE. P values are based on log-rank test results. Only two patients
who had PCP while taking dapsone/pyrimethamine and none who devel-
oped toxoplasmic encephalitis were concomitantly receiving didanosine.
None of the cases of breakthrough PCP or toxoplasmic encephalitis that
occurred during the treatment were associated with poor compliance.
* Analysis of events occurring during initially assigned treatment (or
within 30 days of its discontinuation).
t Subgroup analysis of participants who had no prior trial dose and toler-
ated dapsone/pyrimethamine (n = 120) vs. matched group tolerating aero-
solized pentamidine (n = 120). The groups were matched in regard to toxo-
plasma serology, CD4 lymphocyte count, and (when possible) sex and date
of randomization.
dence of PCP per 100 patient-years during the initial treat-
ment was thus 3.37 (95% CI, 1.33-6.32) among dapsone/
pyrimethamine recipients and 4.48 (95% CI, 2.22-7.52)
among aerosolized pentamidine recipients, corresponding to
an adjusted relative risk of 0.96 (95% CI, 0.37-2.51; P = .93)
for patients taking dapsone/pyrimethamine.
PCP developed in 6 patients receiving secondary prophy-
laxis, 1 in the dapsone/pyrimethamine group and 5 in the
aerosolized pentamidine group, all of whom were receiving
the originally assigned treatment. In the Kaplan-Meier analy-
sis, the proportion free of PCP at 1 year was 0.96 (95% CI,
0.93-0.98) of the dapsone/pyrimethamine recipients vs.
0.97 (95% CI, 0.92-0.98) of the aerosolized pentamidine re-
cipients undergoing primary prophylaxis and 0.98 (95% CI,
0.96-1.00) vs. 0.93 (95% CI, 0.80-0.98), respectively, of
those undergoing secondary prophylaxis.
The median time to onset of PCP was 315 days (range,
56-622 days) for those randomized to receive dapsone/
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pyrimethamine and 224 days (range, 30-463 days) for those
receiving aerosolized pentamidine. The median CD4 count
at the time of randomization was 5 1 Mt (range, 6-370/AL)
in those patients who eventually developed PCP; 84% of
them had CD4 lymphocyte counts of <200/AL. The CD4
counts of the remaining four patients ranged between 200/
AL and 370/AL (22%-26% of total lymphocytes) at random-
ization. One patient receiving aerosolized pentamidine was
found to have extrapulmonary P. carinii infection of the
spleen and liver and was not included in this analysis. Four
patients died of PCP within 3 weeks of the diagnosis; three of
them had been receiving aerosolized pentamidine and one
dapsone/pyrimethamine.
Occurrence of Toxoplasmic Encephalitis
Toxoplasmic encephalitis developed in 34 patients during
the study. In the intent-to-treat analysis, 14 cases occurred in
the dapsone/pyrimethamine group and 20 in the aerosolized
pentamidine group (P = .17, log-rank test), corresponding to
an adjusted relative risk of 0.56 (CI, 0.28-1.12; P = .10) for
patients randomized to receive dapsone/pyrimethamine. At
the time of diagnosis, however, 12 of 14 patients with toxo-
plasmic encephalitis had not been receiving dapsone/pyri-
methamine for a median of 172 days (range, 34-421 days).
Eleven of these 12 patients had previously switched to aero-
solized pentamidine because of intolerance of dapsone/
pyrimethamine; two were not receiving any study medica-
tion at all (table 2).
While they were undergoing the assigned treatment,
toxoplasmic encephalitis developed in two dapsone/
pyrimethamine recipients and 17 aerosolized pentami-
dine recipients, corresponding to incidence rates of 0.96
(95% CI, 0.09-2.76) and 6.92 (95% CI, 4.02-10.6) per
100 patient-years in the respective groups. The adjusted
relative risk of developing toxoplasmic encephalitis dur-
ing treatment was 0.14 (95% CI, 0.03-0.61; P < .01) for
patients taking dapsone/pyrimethamine compared to
that for those taking aerosolized pentamidine.
The diagnosis was presumptive in 26 cases and definite
in eight cases. Among the presumptive cases, only two
were diagnosed on the basis of a positive serology despite
lack of response to specific therapy; in all others there
was a response to antitoxoplasmic treatment. At the time
of randomization, 31 (91%) of 34 patients in whom toxo-
plasmic encephalitis eventually developed were seroposi-
tive for IgG antibodies to Toxoplasma species. One of the
three seronegative patients was retested at the time of
diagnosis and again had no antibodies detected by ELISA
but responded promptly to antitoxoplasmic therapy. The
two other patients were not retested; in one of them, how-
ever, disseminated toxoplasmosis was confirmed by au-
topsy. Three patients died of toxoplasmic encephalitis
within 6 weeks after the diagnosis. Two cases diagnosed
Table 3. Probability of development of toxoplasmic encepha-
litis in patients for whom toxoplasma serology was positive and
who were randomized to receive aerosolized pentamidine.
Probability* at indicated point,
post-randomization
Initial CD4 lymphocyte
count (n)	 6 mo	 12 mo	 18 mo
0-199/AL (90) 7 (3-15) 13 (7-23) 23 (14-36)
0-99/4, (49) 13 (6-28) 20 (10-37) 35 (20-56)
100-199/AL (41) 0 (0-0) 6 (1-21) 12 (5-29)
* Percentage of probability (Kaplan-Meier estimates); 95% confi-
dence interval is in parentheses.
at autopsy were of disseminated toxoplasmosis; myocar-
ditis occurred in both cases, and involvement of the lung,
liver, and spleen occurred in one.
The median time from randomization to onset of toxo-
plasmosis was 278 days (range, 30-634 days) and was
similar in the two prophylaxis groups. The median CD4
count at the time of randomization was 6 1 /AL (range,
3-218/AL) for those patients in whom toxoplasmic en-
cephalitis subsequently developed; 94% of them had a
CD4 lymphocytes count of <200/AL, and for 71% it was
<100/AL. Two patients who subsequently had toxoplas-
mosis had initial CD4 counts of 200/AL (7% of total lym-
phocytes) and 218/AL (13% of total lymphocytes), respec-
tively. The risk to develop toxoplasmic encephalitis in
seropositive patients without prophylaxis is summarized
in table 3.
Mortality
One-hundred fifty participants died during the study, 77 of
whom were randomized to receive dapsone/pyrimethamine
and 73 to receive aerosolized pentamidine. The mortality
was identical in both groups, with an adjusted relative risk of
1.01 (95% CI, 0.74-1.40; P = .93) for those randomized to
receive dapsone/pyrimethamine. Sixty-nine patients died
during initial treatment or within 30 days of its discontinua-
tion: 29 received dapsone/pyrimethamine and 40 received
aerosolized pentamidine, corresponding to an adjusted rela-
tive risk of 1.16 (95% CI, 0.72-1.89; P = .54) for recipients
of dapsone/pyrimethamine.
Subgroup Analysis of the Biological Effect of Dapsone/
Pyrimethamine
To eliminate the interference of intolerance and cross-
overs between treatments, a subanalysis of two matched
groups was performed. For every patient randomized to re-
ceive dapsone/pyrimethamine who did not need to stop the
treatment because of intolerance, a matching patient within
the aerosolized pentamidine group was selected. Matching
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was done in regard to toxoplasma serology and CD4 lym-
phocyte count only among patients who had not been given
prior test doses; as a result, there were two groups of 120
patients with comparable baseline values (median CD4 lym-
phocyte counts, 134/AL for the dapsone/pyrimethamine re-
cipients vs. 140/AL for the aerosolized pentamidine recipi-
ents) and a similar length of follow-up (537 and 546 days,
respectively). The same end points were used as in the in-
tent-to-treat analysis. The adjusted relative risk for those ran-
domized to receive dapsone/pyrimethamine compared with
that for those randomized to receive aerosolized pentami-
dine was 1.17 (95% CI, 0.76-1.81; P = .48) for death, 1.62
(95% CI, 0.51-5.13; P = .41) for occurrence of PCP, and
0.21 (95% CI, 0.06-0.72; P = .014) for occurrence of toxo-
plasmic encephalitis (figure 2).
DP: 	 116 104 98 88 3172
AP: 	 116 112 107 95 81 34
	T 
Intolerance
Thirty percent of patients assigned to dapsone/
pyrimethamine prophylaxis switched to aerosolized penta-
midine because of intolerance. The reported reasons for
switching were nausea (51%), skin rash (40%), headache
(37%), fever (34%), anemia (29%), anorexia (17%), leuko-
penia (7%), pancytopenia (6%), vomiting (6%), diarrhea (3%),
and hepatitis (1%). The adverse events were reversible, and
no severe cutaneous reactions were reported. Before the in-
troduction of the trial doses, 38% of patients receiving dap-
sone/pyrimethamine switched because of intolerance. After
the routine administration of three trial doses before the ran-
domization, 33 (18%) of 184 study candidates were intoler-
ant of the treatment and were not enrolled in the trial; the
remaining 82% were randomized. Fifteen percent of these
patients subsequently switched treatment because of even-
tual intolerance. In a multivariate Cox proportional hazard
regression analysis of 87 participants who discontinued dap-
sone/pyrimethamine prophylaxis because of intolerance vs.
204 participants who tolerated dapsone/pyrimethamine, the
following factors were independently predictive of a treat-
ment switch due to intolerance: no previous trial dose, rela-
tive risk of 2.90 (95% CI, 1.65-5.10; P < .001); female sex,
relative risk of 1.87 (95% CI, 1.11-3.13; P < .02); and low
CD4 lymphocyte count, relative risk of 1.66 (95% CI, 1.30-
2.13; P < .001) for each decrease by 100/AL. The rate of
discontinuation of dapsone/pyrimethamine prophylaxis was
highest during the first 3-4 months of treatment, but the
proportion of participants remaining in the treatment group
continued to drop throughout the entire first year (figure 3).
Four percent of participants receiving aerosolized pentami-
dine discontinued the treatment because of bronchospasm,
cough, vomiting, claustrophobia, or bitter taste in the mouth.
The laboratory values did not differ between the two pro-
phylaxis groups at the time of randomization. During the
assigned treatment, the only significant differences in labora-
tory-defined toxic effects involved a more prominent de-
0_
0 0.8
0
O 0.6
o 0.4
o
a
2 0.2
0.0
DP: 	 114 103 98 88 71 31
AP:
	 113 107 100 89 74 31
1
0	 100 200 300 400 500 600 700
Days
Figure 2. Analysis of the biological effect in 120 participants
who tolerated dapsone/pyrimethamine and 120 matched partici-
pants in the aerosolized pentamidine treatment group. The ad-
justed relative risks for patients randomized to receive dapsone/
pyrimethamine were 1.17 (95% CI, 0.76-1.81) for occurrence of
death (top panel), 1.62 (95% CI, 0.51-5.13) for occurrence of PCP
(middle panel), and 0.21 (95% CI, 0.06-0.72; P = .014) for occur-
rence of toxoplasmic encephalitis (bottom panel). Numbers of pa-
tients at risk are listed above the time axes; DP = dapsone/
pyrimethamine treatment group (solid line), and AP = aerosolized
pentamidine treatment group (dashed line).
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Figure 3. Proportion of participants still receiving initially as-
signed treatment during course of study. The rate at which treat-
ment was stopped because of intolerance of dapsone/
pyrimethamine (DP) was higher among patients who did not
receive the three trial doses (72 of 192) than among those who had
received and tolerated them before randomization (15 of 99). The
differences among the groups were significant (P < .001, log-rank
test).
crease in hemoglobin (-1.8 g/dL vs. —1.4 g/dL; P < .01)
and a higher increase in methemoglobin (+0.7% vs. +0.3% of
hemoglobin; P < .02) in dapsone/pyrimethamine recipients.
The percentage of participants in whom grade 3 or 4 toxicity
developed did not differ significantly; neutropenia (neutro-
phil count, <0.75 X 109/L) was observed in 16.3% of dap-
sone/pyrimethamine recipients and in 17.1% of aerosolized
pentamidine recipients, and severe anemia (hemoglobin,
<8.0 g/dL) in 9.2% and 5.4%, respectively (P = .11). Folinic
acid was rarely administered but was more frequently given
to recipients of dapsone/pyrimethamine (7.2% vs. 3.3% of
participants received it at least once during the study; P
< .05).
Discussion
In this randomized, open-label trial, dapsone/pyrimeth-
amine and aerosolized pentamidine were equally effective as
primary and secondary prophylaxis for PCP. The efficacy of
dapsone/pyrimethamine as primary prophylaxis for toxo-
plasmic encephalitis was not significant in an intent-to-treat
analysis (adjusted relative risk, 0.56; P = .10). However, 12
of 14 cases of toxoplasmic encephalitis in participants ran-
domized to receive dapsone/pyrimethamine occurred a me-
dian of 6 months after the treatment had been discontinued.
Frequent symptoms of intolerance of dapsone/pyrimeth-
amine caused 30% of participants to cross over to prophylaxis
with aerosolized pentamidine, whereas only 4% crossed over
to prophylaxis with dapsone/pyrimethamine. Because of this
substantial number of treatment switches, the power of the
intent-to-treat analysis to detect a difference between the ef-
ficacy of treatments was reduced [26], and the results are
difficult to interpret. If the analysis is restricted to those
events that occurred during the originally assigned treatment
(or within 1 month after its discontinuation), the reduction
in the incidence of toxoplasmic encephalitis among recipi-
ents of dapsone/pyrimethamine is dramatic (table 2).
Participants who prematurely discontinued dapsone/
pyrimethamine prophylaxis because of intolerance had fewer
CD4 lymphocytes. Low CD4 counts are correlated with an
increased risk of toxoplasmosis [9-11], and the lack of fol-
low-up of intolerant patients after treatment stopped might
therefore have biased the results in favor of dapsone/
pyrimethamine in the as-treated analysis [27]. An analysis of
the biological effect of dapsone/pyrimethamine was there-
fore performed involving patients who tolerated the treat-
ment and who were matched to aerosolized pentamidine
recipients in regard to toxoplasma serology and CD4 lym-
phocyte count. The comparison of these two groups, similar
in terms of prognostic factors, yielded evidence of a signifi-
cantly reduced incidence of toxoplasmic encephalitis among
participants randomized to receive dapsone/pyrimethamine
(relative risk, 0.21; P = .014), a finding confirming the anti-
toxoplasmic efficacy of the prophylaxis in those patients who
could tolerate it (biological effect).
Once-weekly administration of both dapsone and pyri-
methamine proved to be an effective and easy regimen. As
expected on the basis of the half-lives of 23-25 hours for
dapsone and 80-105 hours for pyrimethamine [28, 29],
serum concentrations of dapsone decreased considerably
throughout the weekly dosing interval, whereas pyrimetha-
mine levels remained relatively stable in most of the sera
examined [20]. Maintenance of high serum levels may be
less important for prophylaxis than for cure, as shown by the
experience with weekly doses of dapsone [18] and that with
intermittent doses of trimethoprim-sulfamethoxazole [6, 24,
30]: both regimens prevented PCP, although the dosing in-
terval exceeded the half-life of the individual compounds
severalfold. Investigators in one of the latter studies reported
undetectable trough levels in the majority of patients despite
prophylactic efficacy [30].
Fifty mg of dapsone daily and 50 mg of pyrimethamine
once a week were effective as primary prophylaxis for PCP
and toxoplasmic encephalitis in a previous trial [10]. In con-
trast, 100 mg of dapsone and 25 mg of pyrimethamine once
weekly are probably not enough to prevent either PCP or
toxoplasmic encephalitis [31, 32], although the number of
cases in these prospective studies was low. Total weekly
doses of 200-300 mg of dapsone and 50-75 mg of pyrimeth-
amine thus seem to be necessary for protection against both
opportunistic diseases.
Dapsone/pyrimethamine remains the best-studied combi-
nation with proven prophylactic efficacy against toxoplasmic
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encephalitis. Moreover, it is the cheapest available; the
monthly cost of once weekly administration is <$1. Dapsone
alone (100 mg twice weekly) may also be effective as primary
prophylaxis for toxoplasmic encephalitis [33], but the statis-
tical analysis of this trial was not conclusive (P = .07, log-
rank test) and the percentage of seropositive patients was
unknown.
Prophylaxis with trimethoprim-sulfamethoxazole also ap-
pears to protect against toxoplasmic encephalitis, but the op-
timal dose is unknown and the assessments of efficacy have
been based only on a retrospective analysis [24], observa-
tional data [34, 35], or results of controlled trials that did not
primarily target prophylaxis for toxoplasmic encephalitis and
therefore yielded small numbers of events [5, 6, 31, 36-38].
While none of these trials revealed a significant protective
effect on an intent-to-treat basis, toxoplasmic encephalitis in
fact rarely occurred during treatment with trimethoprim-sul-
famethoxazole. Nevertheless, the efficacy of trimethoprim-
sulfamethoxazole as primary prophylaxis for toxoplasmic en-
cephalitis remains to be proved in a prospective, controlled
study. Pyrimethamine/sulfadoxine has also been used as pro-
phylaxis for PCP and toxoplasmic encephalitis, but the com-
bination has not been tested in controlled prospective trials
and cannot be generally recommended.
The development of toxoplasmic encephalitis in HIV-in-
fected patients represents the reactivation of a previous, si-
lent infection in >95% of all cases [10-13]. Among individ-
uals with positive toxoplasma serology, toxoplasmic
encephalitis accounts for 24%-38% of all AIDS-defining
diagnoses [12, 13]. In patients with CD4 counts of <100/4
for whom toxoplasma serology is positive and who have re-
ceived no prophylaxis, the risk of reactivation rises to 20%-
34% after 12 months and to 35%-40% after 18 months, ac-
cording to our study (table 3) and other prospective studies
[10, 39]. Patients with positive toxoplasma serology and
CD4 counts of <100/pt should therefore be mainly targeted
to receive primary prophylaxis. However, only 68% of all
cases of toxoplasmic encephalitis in our study occurred in
patients with these characteristics at the time of randomiza-
tion, a finding illustrating that a smaller yet not negligible
risk also exists in association with a CD4 range of 100-200/
AL. The risk of toxoplasmosis in a population depends on the
prevalence of positive toxoplasma serology, which varies
from 14% to 35% in the United States [40] and from 13% to
23% in the United Kingdom [41, 42] and rise to 50% in Swit-
zerland [14] and up to >70% in France [43]. In addition,
seroprevalence rises with age within a given population
[14, 42].
For PCP prophylaxis, trimethoprim-sulfamethoxazole is
more effective than aerosolized pentamidine [5, 6], and it
became the first-line prophylactic agent in 1992 [25].
Weekly doses of 3-7 double-strength tablets of trimetho-
prim-sulfamethoxazole appear equally effective [6]. The per-
centage of patients discontinuing the treatment because of
intolerance varied between 9% and 31% in prospective trials
6, 30, 36, 38, 44]. The intolerance was not clearly dose-
dependent, although newer results indicate that daily admin-
istration of one double-strength table causes earlier and
greater toxic effects than does thrice weekly administration
[6, 38, 45].
Oral dapsone is an alternative prophylactic agent for PCP,
although it may be slightly less effective than trimethoprim-
sulfamethoxazole. Dapsone at a dosage of 100 mg twice
weekly was as effective as aerosolized pentamidine in two
comparative studies [33, 44 -and at a dosage of 100 mg daily
it was as effective as trimethoprim-sulfamethoxazole [47]. In
a recently completed large randomized trial, overall results
with dapsone at a dosage of 100 mg daily were comparable to
those with aerosolized pentamidine and trimethoprim-sulfa-
methoxazole; however, dapsone appeared less biologically
active than the latter drug (Dr. S. A. Bozzette, personal com-
munication). The combination dapsone/pyrimethamine
(350/50 mg per week) was recently shown to be as effective
as aerosolized pentamidine as primary PCP prophylaxis [10].
The efficacy of lower dosages of dapsone/pyrimethamine
(100/25 mg once to twice weekly) was similar to that of
trimethoprim-sulfamethoxazole and of aerosolized pentami-
dine in one study [31] but was inferior to that of trimetho-
prim-sulfamethoxazole in other prospective studies [32, 44].
The reported rates of discontinuation of therapy due to intol-
erance were 2%-5%, 11%-12%, 24%-35%, and 43% for
weekly dapsone doses of 100 mg [31, 32], 200 mg [33, 44,
46], 350 mg [10, 48], and 700 mg [47], respectively. Intoler-
ance of dapsone with or without pyrimethamine thus seems
to be dose-dependent and only slightly higher than that of
trimethoprim-sulfamethoxazole, on the basis of prospective
data. As 55%-60% of patients intolerant of trimethoprim-sul-
famethoxazole will be able to tolerate dapsone [47, 49], the
option to cross over to an alternative medication should be
given to individuals not tolerating trimethoprim-sulfameth-
oxazole.
Tolerance of dapsone/pyrimethamine in our study was
poor although not much different from that noted in other
trials of systemic prophylaxis [5, 10]. Nausea, skin rash, head-
ache, fever, and anemia were the most frequent reasons for
discontinuation of the treatment. Hypersensitivity reactions
are a well-recognized problem in the HIV-infected popula-
tion, and on the basis of the toxicity profiles of dapsone and
pyrimethamine, the reactions occurring in our study were
most likely attributable to dapsone [50, 51]. Hypersensitivity
developed more frequently in participants with few CD4
lymphocytes, a circumstance that echoes the experience with
amoxycillin-clavulanate [52] but is in contrast to a report
associating hypersensitivity to trimethoprim-sulfamethoxa-
zole with high CD4 counts [53]. The combination of dap-
sone/pyrimethamine had not been previously used in any of
the study centers. As the rate of crossovers varied consider-
ably between the study sites (between 19% and 38% in the
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large centers), the management of intolerance and the will-
ingness to allow possibly temporary toxicity may not have
been optimal early in the study.
The only significant laboratory-proven difference between
the two prophylaxis groups in our study was a slightly higher
incidence of anemia among dapsone/pyrimethamine recipi-
ents. Concomitant administration of dapsone and zidovu-
dine can cause higher incidence of anemia, neutropenia, and
thrombocytopenia [54], and the contribution of each of
these agents to observed toxicity is difficult to assess. In con-
trast to the toxic effect of pyrimethamine on bone marrow,
dapsone-induced hemolytic anemia is caused by the product
of its cytochrome P450-mediated N-hydroxylation [55],
which is not reversible by folinic acid. Because the hemato-
logic toxic effects seen in our study were not greater in com-
parison with those associated with a similar regimen that was
regularly supplemented with folinic acid [10], routine admin-
istration of folinic acid does not seem warranted during pro-
phylactic treatment with dapsone/pyrimethamine at the dos-
age we used. Because the development of anemia is
proportional to both concentration and time of exposure to
dapsone hydroxylamine [55], slightly lower toxicity might
have occurred with smaller doses of dapsone given more fre-
quently. As the mortality rate was identical for both prophy-
laxis groups, data suggesting higher mortality among patients
receiving prophylaxis with either dapsone [48] or pyrimetha-
mine [56] are not supported by our study.
In conclusion, our data provide an additional basis on
which to recommend primary prophylaxis for toxoplasmic
encephalitis in patients who have positive toxoplasma serol-
ogy and low CD4 counts, especially <100h/L. Prophylaxis
with once-weekly dapsone/pyrimethamine is simple and
cheap and prevents both PCP and toxoplasmic encephalitis
in those patients who can tolerate it. The high rate of intoler-
ance in patients with advanced immune deficiency stresses
the need to evaluate better-tolerated prophylactic regimens.
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